Oligomerix’s anti-tau therapy prospectus to be presented this month

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Alzheimer’s therapeutics company Oligomerix announced June 30 that Oligomerix representatives will be presenting the company’s drug development program during poster and scientific sessions at the upcoming Federation of European Neuroscience Societies (FENS) Forum of Neuroscience and the Alzheimer's Association International Conference (AAIC).

The FENS is scheduled for July 5-9 at the MioCo convention center in Milan, Italy, and the AAIC will be held at the Bella Center from July 12 – 17 in Copenhagen, Denmark.

Oligomerix will be presenting cell and animal studies assessing an anti-tau compound’s ability to diminish tau aggregates.

“Alzheimer's disease drug development targeting tau oligomer formation” will be presented during FENS and “Drug development of inhibitors of tau oligomer formation for Alzheimer's disease and tauopathies” will be presented during the AAIC.

 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.